Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies

References

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24, 2137–2150 (2006).
   PubMed Web of Science ®Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol.16, 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs67, 1851–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Titu LV, Monson JR, Greenman J. The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer Immunol. Immunother.51, 235–247 (2002).
   PubMedGoogle Scholar
• Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol.21, 807–839 (2003).
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Carrabba M, Huber V et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev.188, 97–113 (2002).
   PubMed Web of Science ®Google Scholar
• Coussens LM Werb Z. Inflammatory cells and cancer: think different! J. Exp. Med.193, F23–F26 (2001).
   PubMed Web of Science ®Google Scholar
• Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit. Rev. Oncol. Hematol.46, 33–57 (2003).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Lise M, Nitti D. Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology127, 1821–1837 (2004).
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature420, 860–867 (2002).
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet357, 539–545 (2001).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol.3, 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned.Tijdschr. Geneeskd5, 273–290 (1909).
   Google Scholar
• Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell12, 300–301 (2007).
   PubMed Web of Science ®Google Scholar
• Lashner BA, Brzezinski A. Cancer mortality rates in ulcerative colitis surveillance programs. Gastroenterology106, 278–279 (1994).
   PubMedGoogle Scholar
• Chan AT. Can aspirin prevent colorectal cancer? Lancet369, 1577–1578 (2007).
   PubMedGoogle Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer4, 71–78 (2004).
   PubMed Web of Science ®Google Scholar
• Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin. Cancer Res.6, 3545–3551 (2000).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer97, 960–968 (2003).
   PubMedGoogle Scholar
• Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep.10, 309–313 (2003).
   PubMed Web of Science ®Google Scholar
• Hakansson L, Adell G, Boeryd B, Sjogren F, Sjodahl R. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br. J. Cancer75, 374–380 (1997).
   PubMedGoogle Scholar
• Nakayama Y, Nagashima N, Minagawa N et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res.22, 4291–4296 (2002).
   PubMedGoogle Scholar
• Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res.13, 1472–1479 (2007).
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature410, 1107–1111 (2001).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol.6, 715–727 (2006).
   PubMed Web of Science ®Google Scholar
• Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst.87, 982–990 (1995).
   PubMed Web of Science ®Google Scholar
• Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol. Rev.220, 82–101 (2007).
   PubMedGoogle Scholar
• Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: the role of tumor invading T cells. World J. Gastroenterol.12, 7233–7238 (2006).
   PubMedGoogle Scholar
• Graham DM, Appelman HD. Crohn’s-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod. Pathol.3, 332–335 (1990).
   PubMed Web of Science ®Google Scholar
• Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R. Impact of the Crohn’s-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis. Hum. Pathol.26, 31–38 (1995).
   PubMedGoogle Scholar
• Ropponen K, Eskelinen M, Kosma VM, Lipponen P, Paakkinen P, Alhava E. Comparison of classic and quantitative prognostic factors in colorectal cancer. Anticancer Res.16, 3875–3882 (1996).
   PubMedGoogle Scholar
• Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res.58, 3491–3494 (1998).
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313, 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med.353, 2654–2666 (2005).
   PubMed Web of Science ®Google Scholar
• Atreya I, Schimanski CC, Becker C et al. The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut56, 1572–1578 (2007).
   PubMed Web of Science ®Google Scholar
• Pearce EL, Mullen AC, Martins GA et al. Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science302, 1041–1043 (2003).
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Takemoto N, Wherry EJ et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol.6, 1236–1244 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol.22, 633–640 (2001).
   PubMed Web of Science ®Google Scholar
• Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch. Surg.122, 1264–1268 (1987).
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer79, 2320–2328 (1997).
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res.58, 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Wright CM, Dent OF, Barker M et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br. J. Surg.87, 1197–1202 (2000).
   PubMedGoogle Scholar
• Michael-Robinson JM, Biemer-Huttmann A, Purdie DM et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut48, 360–366 (2001).
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Fujita T, Suzuki Y et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res.63, 5564–5572 (2003).
   PubMed Web of Science ®Google Scholar
• Banerjea A, Ahmed S, Hands RE et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol. Cancer3, 21 (2004).
   PubMedGoogle Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol.6, 295–307 (2006).
   PubMed Web of Science ®Google Scholar
• Ling KL, Pratap SE, Bates GJ et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun.7, 7 (2007).
   PubMedGoogle Scholar
• Clarke SL, Betts GJ, Plant A et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE1, E129 (2006).
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res.9, 606–612 (2003).
   PubMed Web of Science ®Google Scholar
• Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J. Transl. Med.4, 52 (2006).
   PubMedGoogle Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol.21, 685–711 (2003).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol.18, 767–811 (2000).
   PubMed Web of Science ®Google Scholar
• Sandel MH, Dadabayev AR, Menon AG et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res.11, 2576–2582 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki A, Masuda A, Nagata H et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J. Pathol.196, 37–43 (2002).
   PubMed Web of Science ®Google Scholar
• Dadabayev AR, Sandel MH, Menon AG et al. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol. Immunother.53, 978–986 (2004).
   PubMedGoogle Scholar
• Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer63, 496–503 (1989).
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J. Transl. Med.5, 62 (2007).
   PubMed Web of Science ®Google Scholar
• Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer72, 619–624 (1997).
   PubMed Web of Science ®Google Scholar
• Della Porta M, Danova M, Rigolin GM et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology68, 276–284 (2005).
   PubMedGoogle Scholar
• Figueredo A, Rumble RB, Maroun J et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer3, 26 (2003).
   PubMed Web of Science ®Google Scholar
• Gardini A, Ercolani G, Riccobon A et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J. Surg. Oncol.87, 46–52 (2004).
   PubMed Web of Science ®Google Scholar
• Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clin. Cancer Res.9, 2357–2365 (2003).
   PubMed Web of Science ®Google Scholar
• Hisada M, Kamiya S, Fujita K et al. Potent antitumor activity of interleukin-27. Cancer Res.64, 1152–1156 (2004).
   PubMed Web of Science ®Google Scholar
• Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J. Immunol.175, 1686–1693 (2005).
   PubMedGoogle Scholar
• Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine25(Suppl. 2), B72–B88 (2007).
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Murphy WJ, Chertox O, Schirrmacher V, Wang JM. Prospects for cytokine and chemokine biotherapy. Clin. Cancer Res.3, 2682–2686 (1997).
   PubMedGoogle Scholar
• Dezfouli S, Hatzinisiriou I, Ralph SJ. Use of cytokines in cancer vaccines/immunotherapy: recent developments improve survival rates for patients with metastatic malignancy. Curr. Pharm. Des.11, 3511–3530 (2005).
   PubMedGoogle Scholar
• Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? Keio J. Med.52, 220–229 (2003).
   PubMedGoogle Scholar
• Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol.195, 346–355 (2003).
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat. Rev. Immunol.1, 41–49 (2001).
   PubMed Web of Science ®Google Scholar
• Suck G. Novel approaches using natural killer cells in cancer therapy. Semin. Cancer Biol.16, 412–418 (2006).
   PubMed Web of Science ®Google Scholar
• Pilla L, Squarcina P, Coppa J et al. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res.65, 3942–3949 (2005).
   PubMed Web of Science ®Google Scholar
• Hantschel M, Pfister K, Jordan A et al. Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones5, 438–442 (2000).
   PubMed Web of Science ®Google Scholar
• Krause SW, Gastpar R, Andreesen R et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical Phase I trial. Clin. Cancer Res.10, 3699–3707 (2004).
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pfister K, Gehrmann M et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones6, 337–344 (2001).
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pfister K, Botzler C et al. Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors. Int. J. Cancer88, 791–797 (2000).
   PubMedGoogle Scholar
• Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu. Rev. Immunol.2, 283–318 (1984).
   PubMed Web of Science ®Google Scholar
• Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol. Ther.2, 320–326 (2003).
   PubMed Web of Science ®Google Scholar
• Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet360, 671–677 (2002).
   PubMed Web of Science ®Google Scholar
• Abdullah N, Greenman J, Pimenidou A, Topping KP, Monson JR. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol. Immunother.48, 517–524 (1999).
   PubMedGoogle Scholar
• Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17–1A. Int. J. Cancer105, 717–723 (2003).
   PubMed Web of Science ®Google Scholar
• Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat. Rev.26, 269–286 (2000).
   PubMed Web of Science ®Google Scholar
• Okuse C, Itoh F. Current status of monoclonal antibodies as therapeutic agents for solid cancer. J. Gastroenterol.40, 1009–1011 (2005).
   PubMedGoogle Scholar
• Xiong H, Li L, Liang QC et al. Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agent. Mol. Med.12, 229–236 (2006).
   PubMed Web of Science ®Google Scholar
• Esche C, Stellato C, Beck LA. Chemokines: key players in innate and adaptive immunity. J. Invest. Dermatol .125, 615–628 (2005).
   PubMed Web of Science ®Google Scholar
• Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M.The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int. J. Oncol.26, 41–47 (2005).
   PubMed Web of Science ®Google Scholar
• Hojo S, Koizumi K, Tsuneyama K et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res.67, 4725–4731 (2007).
   PubMed Web of Science ®Google Scholar
• Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci.98, 1652–1658 (2007).
   PubMed Web of Science ®Google Scholar
• Cook DN. The role of MIP-1 α in inflammation and hematopoiesis. J. Leukoc. Biol.59, 61–66 (1996).
   PubMed Web of Science ®Google Scholar
• Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res.63, 5505–5512 (2003).
   PubMed Web of Science ®Google Scholar
• Morisaki T, Matsumoto K, Onishi H et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum. Cell.16, 175–182 (2003).
   PubMedGoogle Scholar
• Indar A, Maxwell-Armstrong CA, Durrant LG, Carmichael J, Scholefield JH. Current concepts in immunotherapy for the treatment of colorectal cancer. J. R. Coll. Surg. Edinb.47, 458–474 (2002).
   PubMedGoogle Scholar
• Engleman EG. Dendritic cell-based cancer immunotherapy. Semin. Oncol.30, 23–29 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ito A, Kobayashi T et al. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int. J. Cancer116, 624–633 (2005).
   PubMed Web of Science ®Google Scholar
• Li B, Lalani AS, Harding TC et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res.12, 6808–6816 (2006).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med. Res. Rev. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Yamaguchi S, Tatsumi T, Takehara T et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer110, 1469–1477 (2007).
   PubMedGoogle Scholar
• Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA98, 8809–8814 (2001).
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch. Dermatol. Res.289, 1–8 (1996).
   PubMed Web of Science ®Google Scholar
• Oosterling SJ, Mels AK, Geijtenbeek TB et al. Preoperative granulocyte/macrophage colony-stimulating factor (GM-CSF) increases hepatic dendritic cell numbers and clustering with lymphocytes in colorectal cancer patients. Immunobiology211, 641–649 (2006).
   PubMedGoogle Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol.5, 296–306 (2005).
   PubMed Web of Science ®Google Scholar
• Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines4, 329–350 (2005).
   PubMed Web of Science ®Google Scholar
• Tamir A, Basagila E, Kagahzian A et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol. Immunother.56, 2003–2016 (2007).
   PubMed Web of Science ®Google Scholar
• Babatz J, Rollig C, Lobel B et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother.55, 268–276 (2006).
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7, 790–802 (2007).
   PubMed Web of Science ®Google Scholar
• Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest.100, 2783–2792 (1997).
   PubMed Web of Science ®Google Scholar